Case Study: a Cambridge-based RNAi therapeutics company achieves 2X faster gene identification with Elucidata's AI-ready single-cell data pipelines

a Cambridge-based RNAi therapeutics company speeds gene ID 2X with Elucidata

The customer, a Cambridge-based RNA interference (RNAi) therapeutics company, faced challenges in identifying target genes for its rare disease drug development. They struggled to find and manage high-quality, single-cell datasets from multiple organisms, a process that was time-consuming and resulted in inaccurate cell type identification. They collaborated with vendor Elucidata to gain access to AI-ready data and a specialized analysis pipeline.

Elucidata provided high-quality, consistently processed and annotated single-cell datasets, along with a pipeline for re-annotation. This solution enabled the customer to identify and rank potential target genes twice as fast. The results included over 1.8 million harmonized cells across 43 datasets from 5 tissues and 3 organisms, significantly accelerating their RNAi drug discovery process.